share_log

加科思-B(01167.HK):收到与艾力斯关于就GLECIRASIB及JAB-3312的独家对外许可协议的首付款及部分研发开支补偿及其他款项

Jiakangsi-B (01167.HK): The company received the first payment for the exclusive license agreement with shanghai allist pharmaceuticals co., ltd. on GLECIRASIB and JAB-3312, as well as partial compensation for research and development expenses and other p

Gelonghui Finance ·  Sep 26 18:25

Gelonghui September 27th- Jiakebi-B (01167.HK) announced that it has entered into an exclusive license agreement with Shanghai Allist Pharmaceuticals Co., Ltd. ("Allist") regarding Glecirasib and JAB-3312. The company's subsidiary, Peking Jiakebi New Drug Development Co., Ltd. (an indirectly held non-wholly-owned subsidiary), has received approximately RMB 0.173 billion on August 30, 2024 from Allist under the external license agreement for the KRAS G12C inhibitor Glecirasib (JAB-21822) and SHP2 mutation inhibitor JAB-3312, including an initial payment of RMB 0.15 billion and partial reimbursement of research and development expenses and other payments. The receipt of the initial payment, as well as the partial reimbursement of research and development expenses and other payments, further enhances the group's cash reserves and will also provide support for the advancement of the group's subsequent pipeline research and development.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment